Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTX NASDAQ:GRML NASDAQ:MGX NASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.20+3.4%$1.24$0.91▼$3.22$55.25M1.54210,187 shs70,908 shsGRMLGreenland Mines Ltd. Common Stock$0.50+0.6%$0.51$0.12▼$3.91$60.45M7.613.39 million shs1.42 million shsMGXMetagenomi$1.43+1.1%$1.45$1.25▼$3.95$53.65M0.63230,539 shs48,832 shsTRAWTraws Pharma$1.66+5.1%$1.65$0.97▼$3.27$16.88M1.47207,500 shs53,371 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+5.45%+2.65%-7.94%-3.33%-49.34%GRMLGreenland Mines Ltd. Common Stock-3.03%+10.86%-4.62%+96.85%+194.12%MGXMetagenomi+1.44%-2.08%+4.44%-2.76%-10.19%TRAWTraws Pharma+6.04%+30.58%-3.66%-18.56%+5.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.20+3.4%$1.24$0.91▼$3.22$55.25M1.54210,187 shs70,908 shsGRMLGreenland Mines Ltd. Common Stock$0.50+0.6%$0.51$0.12▼$3.91$60.45M7.613.39 million shs1.42 million shsMGXMetagenomi$1.43+1.1%$1.45$1.25▼$3.95$53.65M0.63230,539 shs48,832 shsTRAWTraws Pharma$1.66+5.1%$1.65$0.97▼$3.27$16.88M1.47207,500 shs53,371 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+5.45%+2.65%-7.94%-3.33%-49.34%GRMLGreenland Mines Ltd. Common Stock-3.03%+10.86%-4.62%+96.85%+194.12%MGXMetagenomi+1.44%-2.08%+4.44%-2.76%-10.19%TRAWTraws Pharma+6.04%+30.58%-3.66%-18.56%+5.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio 2.00Hold$9.00656.30% UpsideGRMLGreenland Mines Ltd. Common Stock 1.00SellN/AN/AMGXMetagenomi 2.80Moderate Buy$10.00594.44% UpsideTRAWTraws Pharma 2.50Moderate Buy$8.00386.03% UpsideCurrent Analyst Ratings BreakdownLatest TRAW, ENTX, GRML, and MGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)4/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/22/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)2/9/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$40K1,386.95N/AN/A$0.29 per share4.10GRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/A$0.13 per shareN/AMGXMetagenomi$25.21M2.15N/AN/A$4.22 per share0.34TRAWTraws Pharma$2.79M5.99$0.95 per share1.74($0.08) per share-20.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$11.44M-$0.26N/AN/AN/AN/A-66.39%-57.77%5/8/2026 (Estimated)GRMLGreenland Mines Ltd. Common Stock-$10.55M-$0.32N/AN/AN/AN/A-137.58%-126.00%N/AMGXMetagenomi-$87.87M-$2.37N/AN/AN/A-348.54%-47.14%-33.82%5/12/2026 (Estimated)TRAWTraws Pharma$9.17M$0.931.77N/AN/AN/A112.18%35.31%5/18/2026 (Estimated)Latest TRAW, ENTX, GRML, and MGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q4 2025TRAWTraws Pharma-$0.51N/AN/AN/A$0.06 millionN/A5/12/2026Q1 2026MGXMetagenomi-$0.60N/AN/AN/A$5.90 millionN/A5/8/2026Q1 2026ENTXEntera Bio-$0.08N/AN/AN/AN/AN/A4/15/2026Q4 2025TRAWTraws Pharma-$1.2238-$0.71+$0.5138-$0.71$0.06 millionN/A3/27/2026Q4 2025ENTXEntera Bio-$0.09-$0.07+$0.02$0.07N/AN/A3/5/2026Q4 2025MGXMetagenomi-$0.58-$0.60-$0.02-$0.60$7.33 million$3.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A6.946.94GRMLGreenland Mines Ltd. Common StockN/A95.0295.02MGXMetagenomiN/A7.227.22TRAWTraws PharmaN/A0.720.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%GRMLGreenland Mines Ltd. Common Stock20.07%MGXMetagenomiN/ATRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio10.38%GRMLGreenland Mines Ltd. Common Stock9.90%MGXMetagenomi17.80%TRAWTraws Pharma14.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio2046.62 million41.78 millionOptionableGRMLGreenland Mines Ltd. Common Stock5121.24 million109.24 millionN/AMGXMetagenomi23637.65 million30.95 millionN/ATRAWTraws Pharma1710.16 million8.74 millionNo DataTRAW, ENTX, GRML, and MGX HeadlinesRecent News About These CompaniesTraws Pharma (NASDAQ:TRAW) Major Shareholder Buys $998,207.43 in StockMay 1, 2026 | americanbankingnews.comTraws Pharma (TRAW) price target decreased by 24.14% to 5.61April 29, 2026 | msn.comTraws Pharma (NASDAQ:TRAW) Major Shareholder Purchases $998,207.43 in StockApril 29, 2026 | insidertrades.comNewtown-based Traws Pharma shares full-year results, clinical progressApril 23, 2026 | msn.comTraws Pharma Takes Flight: Revolutionary Flu Prophylactic Poised to SoarApril 21, 2026 | news.themarketisopen.comNTraws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?April 20, 2026 | zacks.comTraws Pharma, Inc. Q4 2025 Earnings Call SummaryApril 16, 2026 | finance.yahoo.comTraws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...April 16, 2026 | finance.yahoo.comTraws outlines $60M financing while targeting flu challenge study this summer and runway into Q1 2027April 16, 2026 | seekingalpha.comTraws Pharma Announces Up to $60 Million Private Placement FinancingApril 16, 2026 | markets.businessinsider.comTraws Pharma, Inc. (TRAW) Q4 2025 Earnings Call TranscriptApril 16, 2026 | seekingalpha.comTraws Pharma Reports Full Year 2025 Results and Provides Business HighlightsApril 15, 2026 | globenewswire.comTraws Pharma Secures $10 Million PIPE Financing to Advance Influenza Program in Human Challenge TrialApril 15, 2026 | quiverquant.comQhVIVO shares rise 11% as influenza trial win and rebrand signal integrated strategy bearing fruitApril 14, 2026 | uk.finance.yahoo.comhVIVO inks influenza trial contract and unveils unified brand as integrated platform strategy takes shapeApril 14, 2026 | uk.finance.yahoo.comTraws Pharma Delays 10-K Amid Financing ReviewApril 10, 2026 | theglobeandmail.comTraws Pharma reports phase 2 COVID-19 data, flu program updateFebruary 24, 2026 | msn.comTraws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical holdFebruary 19, 2026 | in.investing.comTraws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for ...February 19, 2026 | markets.businessinsider.comTraws Pharma Reports Completed Clinical Results of Ratutrelvir Showing Differentiated Profile Compared to PAXLOVID® with Fewer Adverse Events and No Viral ReboundsFebruary 19, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRAW, ENTX, GRML, and MGX Company DescriptionsEntera Bio NASDAQ:ENTX$1.20 +0.04 (+3.36%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Greenland Mines Ltd. Common Stock NASDAQ:GRML$0.50 +0.00 (+0.61%) As of 11:39 AM EasternGreenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.Metagenomi NASDAQ:MGX$1.42 +0.02 (+1.06%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Traws Pharma NASDAQ:TRAW$1.66 +0.08 (+5.06%) As of 11:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
